Mar 2025 Articles

Articles
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial
Koren MJ, Vega RB, Agrawal N, et al.
Journal:
J Am Coll Cardiol

First published: March 31, 2025 DOI: 10.1016/j.jacc.2025.03.499
View
- Share
Articles
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Ray KK, Oru E, Rosenson RS, et al.
Journal:
Lancet

First published: March 31, 2025 DOI: 10.1016/S0140-6736(25)00507-0
View
- Share
Articles
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies
Ray KK, Linnebjerg H, Michael LF, et al.
Journal:
J Am Coll Cardiol

First published: March 30, 2025 DOI: 10.1016/j.jacc.2025.03.005
View
- Share
Articles
Lepodisiran – A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
Nissen SE, Ni W, Shen X, et al.
Journal:
N Engl J Med

First published: March 30, 2025 DOI: 10.1056/NEJMoa2415818
View
- Share
Articles
Coronary Artery Calcium Density and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis
Yong Y, Giovannucci J, Pang SN, et al.
Journal:
JACC Cardiovasc Imaging

First published: March 18, 2025 DOI: 10.1016/j.jcmg.2024.07.024
View
- Share
Articles
Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies
Watts GF, Chan DC
Journal:
Eur Heart J

First published: March 4, 2025 DOI: 10.1093/eurheartj/ehae931
View
- Share
Articles
2025 Consensus on the Clinical Pathway of Blood Cholesterol Management in Taiwan
Li YH, Shih CL
Journal:
Acta Cardiol Sin

First published: March 1, 2025 DOI: 10.6515/ACS.202503_41(2).20250215A
View
- Share

Mar 2025 Articles

Articles

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial

Koren MJ, Vega RB, Agrawal N, et al.

Articles

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray KK, Oru E, Rosenson RS, et al.

Articles

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

Ray KK, Linnebjerg H, Michael LF, et al.

Articles

Lepodisiran – A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)

Nissen SE, Ni W, Shen X, et al.

Articles

Coronary Artery Calcium Density and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis

Yong Y, Giovannucci J, Pang SN, et al.

Articles

Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies

Watts GF, Chan DC

Articles

2025 Consensus on the Clinical Pathway of Blood Cholesterol Management in Taiwan

Li YH, Shih CL

Articles

An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial

Koren MJ, Vega RB, Agrawal N, et al.

Share

Articles

Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial

Ray KK, Oru E, Rosenson RS, et al.

Share

Articles

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

Ray KK, Linnebjerg H, Michael LF, et al.

Share

Articles

Lepodisiran – A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)

Nissen SE, Ni W, Shen X, et al.

Share

Articles

Coronary Artery Calcium Density and Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis

Yong Y, Giovannucci J, Pang SN, et al.

Share

Articles

Reaching for the stars: a wider perspective for designing future cardiovascular outcome trials of triglyceride-lowering therapies

Watts GF, Chan DC

Share

Articles

2025 Consensus on the Clinical Pathway of Blood Cholesterol Management in Taiwan

Li YH, Shih CL

Share